UK Markets closed

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.4020+0.0540 (+1.61%)
At close: 06:11PM BST

GenSight Biologics S.A.

74, rue du Faubourg Saint-Antoine
Paris 75012
33 1 76 21 72 20

Full-time employees38

Key executives

NameTitlePayExercisedYear born
Dr. Bernard Gilly Ph.D.Co-Founder, CEO & Exec. Director508.09kN/A1957
Dr. Jose-Alain Sahel M.D., Ph.D.Scientific Founder, Vice Chairman of Scientific Advisory Board & Board ObserverN/AN/AN/A
Prof. Botond RoskaScientific Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Jean E. Bennett M.D., Ph.D.Scientific Founder & Vice Chairman of Scientific Advisory BoardN/AN/A1955
Dr. Luk H. Vandenberghe M.D., Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Dr. Serge PicaudScientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Prof. Constance L. CepkoScientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Thomas GidoinChief Financial OfficerN/AN/A1983
Mr. Scott JeffersChief Technical OfficerN/AN/AN/A
Mr. Julio BenedictoVP of MarketingN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

Corporate governance

GenSight Biologics S.A.’s ISS governance QualityScore as of 1 July 2022 is 8. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.